Mometason Glenmark (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometason Glenmark, is a corticosteroid presented as a topical formulation for skin application. It exerts potent anti‑inflammatory and immunosuppressive activity, helping to control redness, scaling and itching associated with common dermatologic disorders. The product is marketed in the European Union and is intended for use under medical supervision.

GNH USA supplies Mometason Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets with reliable logistics and documentation support.

Mometason Glenmark (mometasone furoate) is used topically to treat inflammatory skin disorders.

- Psoriasis: reduces scaling, redness and plaque thickness. - Atopic dermatitis (eczema): alleviates itching, inflammation and skin irritation. - Seborrheic dermatitis: controls flaking and erythema on scalp and face. - Contact dermatitis: diminishes allergic skin reactions. - Lichen planus: lessens lesions and associated discomfort.

Topical application of mometasone furoate may cause local skin reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Itching or mild irritation. - Dryness or flaking of the skin. - Folliculitis or acne‑like eruptions. - Redness or mild erythema. - Pruritus (new onset itching).

Serious or Rare Side Effects: - Skin atrophy or thinning. - Hypopigmentation or depigmentation. - Secondary bacterial, fungal or viral infection. - Systemic adrenal suppression with extensive use. - Allergic contact dermatitis or urticaria. - Tachyphylaxis (diminished response over time).

Before using Mometason Glenmark, consider the following safety measures. - Assess skin condition: ensure the diagnosis warrants a potent corticosteroid. - Use lowest effective potency: apply the smallest amount needed to achieve control. - Limit duration: avoid continuous use beyond the prescribed period. - Avoid broken or infected skin: do not apply to open wounds or active infections. - Do not occlude: refrain from covering treated areas with airtight dressings unless directed. - Store at room temperature: keep in the original container, protect from moisture and excessive heat.

Mometason Glenmark may interact with other agents that affect corticosteroid activity or skin absorption.

Major Interactions (Avoid): - Systemic corticosteroids: increase risk of systemic effects. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise local drug levels. - Other topical steroids applied to the same area: can cause additive skin thinning.

Moderate Interactions (Monitor Closely):\n- Topical antifungal agents: may alter skin barrier and absorption. - Non‑steroidal anti‑inflammatory drugs (topical): monitor for irritation. - Herbal or cosmetic products containing irritants: assess for additive skin reactions.